Eli Lilly (LLY) vs Novo Nordisk (NVO)
LLY and NVO cannot be ranked from the currently available comparable metrics because QuantLink did not receive enough complete metric values.
Side-by-side scorecard
As of Jul 9, 2026. Unavailable values are shown as — and excluded from the comparable-metric tally.
| Metric | Eli Lilly and Company (LLY) | Novo Nordisk (NVO) |
|---|---|---|
| Size | ||
PriceContext only | — | — |
Market capContext only | $1.1T | — |
| Valuation | ||
P/E ratio | 43.18x | — |
PEG ratio | 0.34x | — |
Price/book | 34.98x | — |
Price/sales | 15.11x | — |
EV/EBITDA | 35.38x | — |
| Profitability | ||
Gross margin | 83.5% | — |
Operating margin | 45.9% | — |
Net margin | 35.0% | — |
ROIC | 44.4% | — |
ROE | 81.0% | — |
EPS | — | — |
| Leverage | ||
Debt/equity | 1.39x | — |
| Dividend | ||
Dividend yield | — | — |
How the comparison is scored
QuantLink marks a row leader only when both companies have a numeric value and the metric has a fixed comparison direction. Lower values lead on valuation multiples and debt/equity, while higher values lead on profitability and dividend yield.
Price and market capitalization are shown for context only, so they do not receive a leader checkmark and do not affect the tally.